The Trump administration has negotiated 15 deals in which pharmaceutical companies voluntarily agreed to lower prices on prescription medications in the United States.
The negotiations broke the longstanding practice by manufacturers of charging up to 400 percent more for brand-name drugs in the United States than in Canada, the United Kingdom, and other developed nations.





